Macro molecule-based STING pathway modulators are currently being evaluated as monotherapies, By Roots Analysis Knowpia

In recent years, the concept of STING pathway targeting therapeutics has generated a lot of enthusiasm within the medical science community. The growing popularity of this therapeutic technique has not only garnered the interest of several medical researchers (reflected in the increasing volume of scientific literature (1,000+ articles published since 2015) on this subject), but also industry stakeholders focused on drug development (evident in the growing number of clinical trials and the grants awarded for STING focused projects in the recent past).

To order this 310+ page report, which features 170+ figures and 200+ tables, please visit this - https://www.rootsanalysis.com/reports/sting-pathway-targeting-therapeutics-and-technologies-market.html

The USD 2.8 billion (by 2030) financial opportunity within the STING pathway targeting technologies market has been analysed across the following segments:

§ Types of Payment

§ Upfront Payments

§ Milestone Payments

§ Type of STING Modulator

§ Agonist

§ Antagonist

§ Key Therapeutic Area(s)

§ Oncological Disorders

§ Inflammatory Disorders

§ Infectious Diseases

§ Others

§ Route of Administration

§ Intratumoral

§ Intravenous

§ Oral

§ Subcutaneous

§ Others

§ Type of Molecule

§ Non-nucleotide

§ Cyclic Dinucleotide

§ Live Biotherapeutics

§ Oncolytic Peptides

§ Synthetic Peptides

§ Others

§ Key Geographical Regions

§ North America

§ Europe

§ Asia-Pacific

The STING Pathway Targeting Therapeutics and Technologies, 2020-2030. report features the following companies, which we identified to be key players in this domain:

§ Aduro Biotech

§ Bristol Myers Squibb

§ Eisai

§ GlaxoSmithKline

§ ImmuneSensor Therapeutics

§ Merck

§ Noxopharm

§ Spring Bank Pharmaceuticals

§ Synlogic

Table of Contents

1. Preface

2. Executive Summary

3. Introduction